At the Bi weekly meeting of the CPPCC National Committee for the promotion of drugs, the CPPCC called for the reform of drug bidding and medical insurance reimbursement system to further improve the national generic drug policy

Source: on December 3, 2015, CPPCC held the 43rd two week consultative Symposium in Beijing, inviting CPPCC members, experts and scholars, as well as the heads of relevant ministries and commissions of the State Council to discuss and negotiate on improving the quality of generic drugs in China Yu Zhengsheng, member of the Standing Committee of the Political Bureau of the CPC Central Committee and chairman of the CPPCC National Committee, presided over the meeting and made a speech Du Qinglin, Secretary of the Secretariat of the CPC Central Committee and vice chairman of the CPPCC National Committee, Zhang Qingli, vice chairman and Secretary General of the CPPCC National Committee, Lu Zhangong, vice chairman of the CPPCC National Committee, Liu Xiaofeng, vice chairman of the Central Committee of the Democratic Party of agriculture and industry, attended the meeting Yu Zhengsheng, chairman of the biweekly meeting of the CPPCC National Committee, believes that improving the quality of generic drugs is a major event, which is related to the health of the people, the sustainability of medical insurance, and whether the people can use high-quality and cheap generic drugs The CPC Central Committee and the State Council attach great importance to the quality of drugs Relevant departments of the central government have continuously strengthened policy guidance and supervision to promote the improvement of quality and standards of generic drugs At present, generic drugs basically meet the needs of the public, but there are still some problems such as the quality of generic drugs is uneven, the standard of generic drugs is low, and the efficacy of some drugs is not accurate We should further strengthen reform and policy adjustment, improve the quality of drugs, and ensure the safety of drug use Song Ruilin, executive chairman of China pharmaceutical innovation promotion association, was invited as an expert In his speech, president Song Ruilin pointed out that generic drugs play an indispensable and important role in the national health care system At present, measures to improve the quality and standard of generic drugs implemented by the state are very necessary and timely, which will greatly improve the quality level of generic drugs in China The quality improvement of generic drugs is a systematic project, which needs the joint promotion of medical treatment, medical insurance and medicine President Song Ruilin, speaking at the CPPCC fortnightly meeting, pointed out that the current provincial drug bidding and procurement system, which adopts the strategy of "only low price is to take", makes the more high-quality generic drugs, the more unable to win the bid He used specific examples to show that China's high-quality generic drugs have been internationally recognized and the price is only 1 / 10 of the original research drugs, which has played an alternative role in the United States and forced the original research drugs to withdraw from the United States market, reducing the cost of drug use for American patients However, the generic drugs with such high quality and low price cannot win the bid because they are included in the general generic drug price in the drug bidding of a province in South China; the original research drugs are given a separate quality level position in the bidding, which makes them win the bid in the province at more than five times the price of the same generic drugs in the U.S market, with the market share rising from 65.5% in 2013 to 96.46% in the first three quarters of this year It will greatly increase the drug burden of the people; if the product can be replaced by domestic high-quality generic drugs, it can save nearly 500 million yuan of expenditure for national medical insurance and patients every year In addition, since 2009, the national medical insurance catalogue has not been supplemented, which makes the newly listed domestic high-quality generic drugs unable to play a role in clinical application, let alone replace the imported original research drugs Due to the problems of the current medical insurance management system, in some provinces, the original research drugs are listed in the medical insurance reimbursement catalogue for reimbursement, while the domestic high-quality generic drugs with high quality and low price cannot enter the medical insurance reimbursement catalogue as soon as possible after they are listed, so they cannot play an alternative role; in other places, the internationally recognized domestic high-quality targeted tumor drugs are excluded from the negotiation process of high-value drugs, only with the imported original research drugs Drug manufacturer negotiation The above practice is not understandable, and the relevant departments should pay attention to it and change it as soon as possible President Song Ruilin pointed out that in order to promote the quality consistency evaluation of generic drugs in China, we need to deeply reflect on the existing drug use policies in China If there is no clear alternative policy for generic drugs and a good market environment for high-quality generic drugs; if there is no policy synergy between various departments; if the enterprises who are willing to improve the quality of drugs can not get the market returns, it is difficult to achieve the goal of improving the quality of generic drugs in China only by strengthening the quality control and standards of drugs In order to achieve the goal of improving the quality of generic drugs, we must give full play to the regulatory role of the market, so that generic drug enterprises can obtain better market returns by continuously improving the quality; improving the quality of generic drugs is not only a compulsory provision of national laws, but also an internal demand of producers Therefore, it is necessary to change the current mechanism of drug bidding and medical insurance For those domestic generic drugs that have been internationally recognized, it should be regarded as fair competition with the original research drugs at the same quality level through quality consistency evaluation, so as to ensure quality priority and reasonable price At the meeting, members also suggested that first, we should improve the standards for drug approval, encourage drug research and development, simplify procedures and speed up approval Second, accelerate the quality consistency evaluation of generic drugs, further improve the standards and eliminate the backward ones Drugs passing the consistency evaluation are allowed to be marked on the outer packaging, and medical institutions are given priority to purchase and support in technical transformation Third, in terms of medical insurance policy and bidding policy, it should be conducive to the use of high-quality generic drugs We should adjust the drug policy in time, optimize the medical insurance catalogue, improve the relevant system of drug bidding and purchase, and give full play to the leverage of medical insurance Fourth, improve hospital management, improve hospital assessment methods, implement medical treatment, medical insurance and medical linkage, improve the incentive mechanism to encourage the use of high-quality generic drugs, and effectively protect the health rights and interests of the people Fifth, attach importance to the innovation of generic drugs, strengthen the supervision after listing, and promote the upgrading of pharmaceutical industry Bi Jingquan, director of the State Food and drug administration, Xin Guobin, Deputy Minister of the Ministry of industry and information technology, you Jun, Deputy Minister of the Ministry of human resources and social security, and Liu Qian, deputy director of the national health and Family Planning Commission, respectively introduced relevant information and exchanged information with members and experts.